A red blood cell agglutination D-dimer test to exclude deep venous thrombosis in pregnancy. 2007

Wee-Shian Chan, and Sanjeev Chunilal, and Agnes Lee, and Mark Crowther, and Marc Rodger, and Jeffrey S Ginsberg
Women's College Hospital, Toronto, Ontario, Canada. wee-shian.chan@wchospital.ca

BACKGROUND D-Dimer testing is often used with compression ultrasonography for the diagnosis of deep venous thrombosis (DVT) in nonpregnant patients. The D-dimer test is highly sensitive, and a negative result can obviate the need for further testing for DVT. This test has not been studied for DVT diagnosis in pregnancy because its specificity was deemed too poor. OBJECTIVE To determine the sensitivity and specificity and assess the utility of the SimpliRED assay (Agen Biomedical, Brisbane, Australia) for the diagnosis of DVT in pregnant women. METHODS Prospective cohort study. METHODS 5 tertiary university-affiliated Canadian hospitals providing care to obstetric patients. METHODS 149 consecutive pregnant women with suspected DVT who presented to 1 of the participating centers over 5 years. METHODS Participating women were tested with compression leg ultrasonography (single or serially on days 0, 3, and 7) and received 3 months' clinical follow-up for the presence or absence of DVT. Whole blood was tested with the SimpliRED assay at initial presentation, and results were correlated with ultrasonography and clinical findings for the presence or absence of DVT. METHODS The sensitivity, specificity, and negative predictive value of the SimpliRED assay were calculated, along with the prevalence of false-positive SimpliRED assay results (with 95% CIs). RESULTS The prevalence of DVT in the cohort was 8.7% (95% CI, 5.2% to 14.4%). The sensitivity of the SimpliRED assay was 100% (CI, 77% to 100% [13 of 13 patients]), the specificity was 60% (CI, 52% to 68% [81 of 135]), and the negative predictive value was 100% (CI, 95% to 100% [81 of 81]). The SimpliRED assay was positive in 0% (CI, 0% to 60%), 24% (CI, 14% to 37%), and 51% (CI, 40% to 61%) of women in the first, second, and third trimesters, respectively, among pregnant patients in whom DVT was not diagnosed. CONCLUSIONS The prevalence of DVT in the cohort was low, resulting in wide CIs. The clinician's previous impression was used to determine pretest probability in the absence of a validated clinical prediction rule for pregnant women. CONCLUSIONS The SimpliRED assay may be useful in pregnancy because a normal result excludes DVT and occurs frequently enough to be clinically helpful.

UI MeSH Term Description Entries
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011250 Pregnancy Complications, Hematologic The co-occurrence of pregnancy and a blood disease (HEMATOLOGIC DISEASES) which involves BLOOD CELLS or COAGULATION FACTORS. The hematologic disease may precede or follow FERTILIZATION and it may or may not have a deleterious effect on the pregnant woman or FETUS. Complications, Hematologic Pregnancy,Hematologic Pregnancy Complications,Pregnancy Complications, Hematological,Pregnancy, Hematologic Complications,Complication, Hematologic Pregnancy,Complication, Hematological Pregnancy,Complications, Hematological Pregnancy,Hematologic Pregnancy Complication,Hematological Pregnancy Complication,Hematological Pregnancy Complications,Pregnancies, Hematologic Complications,Pregnancy Complication, Hematologic,Pregnancy Complication, Hematological
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D005260 Female Females
D005338 Fibrin Fibrinogen Degradation Products Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis. Antithrombin VI,Fibrin Degradation Product,Fibrin Degradation Products,Fibrin Fibrinogen Split Products,Degradation Product, Fibrin,Degradation Products, Fibrin,Product, Fibrin Degradation
D006386 Hemagglutination Tests Sensitive tests to measure certain antigens, antibodies, or viruses, using their ability to agglutinate certain erythrocytes. (From Stedman, 26th ed) Hemagglutination Test,Test, Hemagglutination,Tests, Hemagglutination
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Wee-Shian Chan, and Sanjeev Chunilal, and Agnes Lee, and Mark Crowther, and Marc Rodger, and Jeffrey S Ginsberg
September 2009, Ugeskrift for laeger,
Wee-Shian Chan, and Sanjeev Chunilal, and Agnes Lee, and Mark Crowther, and Marc Rodger, and Jeffrey S Ginsberg
December 2004, Annals of internal medicine,
Wee-Shian Chan, and Sanjeev Chunilal, and Agnes Lee, and Mark Crowther, and Marc Rodger, and Jeffrey S Ginsberg
July 2000, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
Wee-Shian Chan, and Sanjeev Chunilal, and Agnes Lee, and Mark Crowther, and Marc Rodger, and Jeffrey S Ginsberg
January 2006, Emergency medicine Australasia : EMA,
Wee-Shian Chan, and Sanjeev Chunilal, and Agnes Lee, and Mark Crowther, and Marc Rodger, and Jeffrey S Ginsberg
February 1992, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
Wee-Shian Chan, and Sanjeev Chunilal, and Agnes Lee, and Mark Crowther, and Marc Rodger, and Jeffrey S Ginsberg
March 2008, Ugeskrift for laeger,
Wee-Shian Chan, and Sanjeev Chunilal, and Agnes Lee, and Mark Crowther, and Marc Rodger, and Jeffrey S Ginsberg
April 2006, Thrombosis and haemostasis,
Wee-Shian Chan, and Sanjeev Chunilal, and Agnes Lee, and Mark Crowther, and Marc Rodger, and Jeffrey S Ginsberg
December 2002, Journal of internal medicine,
Wee-Shian Chan, and Sanjeev Chunilal, and Agnes Lee, and Mark Crowther, and Marc Rodger, and Jeffrey S Ginsberg
January 1998, Seminars in thrombosis and hemostasis,
Wee-Shian Chan, and Sanjeev Chunilal, and Agnes Lee, and Mark Crowther, and Marc Rodger, and Jeffrey S Ginsberg
April 2004, Annals of internal medicine,
Copied contents to your clipboard!